Rahnemai-Azar Amir A, Pandey Pallavi, Kamel Ihab, Pawlik Timothy M
Department of Surgery, University of Washington Medical Center, University of Washington School of Medicine, Seattle, WA, USA.
Department of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hepat Oncol. 2016 Oct;3(4):223-239. doi: 10.2217/hep-2016-0009. Epub 2017 Jan 20.
Intrahepatic cholangiocarcinoma (iCCA) is one of the fatal gastrointestinal cancers with increasing incidence and mortality. Although surgery offers the only potential for cure in iCCA patients, the prognosis is not optimal with low overall survival rate and high disease recurrence. Hence, adjuvant therapy is generally recommended in the management of high-risk patients. Identifying factors associated with disease recurrence and survival of the iCCA patients after resection will improve understanding of disease prognosis and help in selecting patients who will benefit from surgical resection or stratifying them for clinical trials. Despite development of new methods for early detection of tumor recurrence, effective prognostic models and nomograms, and recent advances in management, significant challenges remain in improving the prognosis of iCCA patients.
肝内胆管癌(iCCA)是一种致命的胃肠道癌症,其发病率和死亡率呈上升趋势。尽管手术是iCCA患者唯一可能治愈的方法,但总体生存率低且疾病复发率高,预后并不理想。因此,一般建议对高危患者进行辅助治疗。识别与iCCA患者切除术后疾病复发和生存相关的因素,将有助于更好地理解疾病预后,并有助于选择能从手术切除中获益的患者或对其进行临床试验分层。尽管在肿瘤复发的早期检测、有效的预后模型和列线图方面有了新的方法,以及在治疗方面有了最新进展,但在改善iCCA患者的预后方面仍存在重大挑战。